Drug
Su011248
Su011248: highest development phase Phase 2, developed by United Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| SU011248, Sutent NCT00668811 | Phase 2 | Papillary Thyroid Cancer |
Latest
No recent events.
Follow Su011248 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.